Adaptive Biotechnologies (ADPT) stock
ADPT's Quality Score rose 3 points on Wed, Nov 4, to 11.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Key facts on ADPT
| The company | Sales up 50% on the year |
| Latest filing | 8-K, Nov 4 |
ADPT in the news
ReportToday after the close: sales of $83.9M; a profit of $0.02 a share. Raised its outlook for the year. Past reports ›
What's next
Expected to report Thu Feb 4, after the close
ADPT catalysts
Why ADPT scores 11
Above Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. ADPT scores 11 today, against a median of 7 over its last 20 recorded sessions.
- +5Chart checks 5 of 14 firing right now, one point each
- +3Growth sales up 50% on the year, gross margin up 9.5 points
- Long-term trend adds
- Run-up adds
- Volatility subtracts
- Cash flow subtracts
- News adds
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
ADPT has 5 of 14 chart checks firing
ADPT RSI today: 51.9, above its 50-day and 200-day averages
- RSI 1451.9
- MACD (12, 26, 9)Above signal
- 50-day average$26.37
- 200-day average$19.73
- 50/200 crossGolden cross
- ADX 1416.0
- Support$23.92
- Resistance$26.87
- 52-week high$30.74
- 52-week low$12.00
- Chart patternTriangle
- Bollinger Bands (20, 2)Inside
- Volume1.2x
The deep dive on ADPT
- What it does and how it makes moneySEC filing · Feb 26, 2026SEC filing · Feb 26, 2026
- Where it stands
- Who holds and trades it
- Against its closest peers
How ADPT ranks in Biotech
ADPT is #43 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 43 |
Sales over four quarters against a year before: ADPT +50%, TWST +19%, VCEL +23%, IOVA +35%.
When does ADPT report earnings, and what happens after?
Expected to report Thu Feb 4, after the close (in 92 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What ADPT reported on Nov 4, 2026
The quarter
Sales of $83.9M, 11% less than a year ago; a profit of $0.02 a share, from $0.06.
Where the sales came from
ADPT's results filing gives no sales by line in a table we read.
The outlook
| Measure | Figure |
|---|---|
| MRD revenue | $276M to $286M |
In the company's words
“This momentum supports another increase in our full year outlook.”
From its results filing (SEC filing · Nov 4)
The numbers
- $4.5B
- today
- $308M
- up 50.1% on the year
- -$24M
- last 12 months
Sales grew 23% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 2.9% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Jul 29, 2026 | -1.6% | +7.2% | +9.0% |
| May 5, 2026 | +6.2% | +4.7% | -1.1% |
| Feb 5, 2026 | +8.2% | -4.3% | -5.7% |
ADPT sales and profit by year
Sales grew in six of the last seven years, to $277M in 2025. It lost money in each of the eight years.
Insiders trading ADPT
ADPT insider trades
5 insiders sold $19.1M across 11 filings in the last 6 months. No open-market buys on record. The newest:
ADPT's officers and directors
Officers and directors with a Form 4 in the last 12 months.
Which ETFs hold ADPT?
In ETFs: ADPT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
What Adaptive Biotechnologies says it competes with
“The biotechnology and pharmaceutical industries, including the fields of clinical diagnostics, life sciences research and drug discovery, are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property.”
ADPT's score card
Pro members see every line of every stock's score.
- What would move ADPT's score: 6 things
- 2 more filings explained, a plain line each
- Real-time prices, no delay
Straight Answers
Is ADPT a good stock to buy? What its Quality Score says
ADPT scores 11 today, which Breakaway calls Above Average. It is #43 of 291 in Biotech by Quality Score, with 5 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is ADPT's Quality Score?
ADPT scores 11 today, which Breakaway calls Above Average (11 to 14). That is #43 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ADPT's 11.
Are insiders buying ADPT?
5 insiders sold $19.1M across 11 filings in the last 6 months. No open-market buys on record. The newest is Katey Einterz Owen, Director, who sold $250K on Aug 26. Every filing, with the scored weight, for Pro members.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.